Shares of Esperion Therapeutics rally after the drug developer said its treatment significantly lowered bad cholesterol in patients enrolled in a clinical trial.
MarketWatch.com - Top Stories, MarketWatch
Wed, 10/01/2014 - 3:03pm
Shares of Esperion Therapeutics rally after the drug developer said its treatment significantly lowered bad cholesterol in patients enrolled in a clinical trial.